Abstract: This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase (“LTA4H”) to treat and/or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.

Abstract: Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy.

Abstract: Provided herein are methods of inducing liver regeneration in a subject diagnosed with a liver disorder. The method comprises administering a Plasma Protein Fraction (PPF) to the subject. In certain embodiments, the PPF comprises between 83% and 95% albumin in relation to total proteins. The PPF can be produced from plasma obtained from young individuals, for example, humans 40 years of age or younger.

Abstract: The present invention relates to pharmaceutical compositions containing one or more compounds of formula 1 wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alkyl; X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate; j is 1 or 2; and processes for the preparation thereof, and their use to treat diseases connected with the CCR3 receptor.

Abstract: Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy.

Abstract: The disclosure pertains to methods of treating pain. In certain embodiments, the methods comprise administering to a subject a Plasma Protein Fraction (PPF) in an amount that is effective to treat pain.

Abstract: Methods and compositions for treating aging-related diseases as well as liver regeneration, prevention of liver degeneration, and maintenance of liver are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing disease.

Abstract: Methods and compositions for treating aging-related diseases as well as muscle recovery, prevention of muscle degeneration, and maintenance of muscle are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing disease.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as cognitive disorders. The methods relate to a regimen of pulsed dosing of blood plasma or blood plasma fractions.

Abstract: Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: The disclosure pertains to methods of improving wound healing. In certain embodiments, the methods comprise administering to a subject a Plasma Protein Fraction (PPF) in an amount that is effective to treat a wound.

Abstract: The disclosure pertains to methods for improving postoperative recovery. In certain embodiments, the methods comprise administering to a subject a Plasma Protein Fraction (PPF) in an amount that is effective to improve or accelerate postoperative recovery.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as cognitive disorders. The methods relate to a regimen of pulsed dosing of blood plasma or blood plasma fractions.

Abstract: The invention relates to treating individuals with cancer by using blood plasma or blood plasma fractions as treatment.

Abstract: Methods and compositions are provided for screening candidate compositions for activity with respect to treatment of aging-associated conditions, e.g., cognitive impairment conditions or age-related dementia. Aspects of the methods include administering a human blood product comprising plasma, to an immunocompromised animal, e.g., a mouse or a rat, and measuring the effect of the product on an endpoint, e.g., neurogenesis, locomotor activity, anxiety, spatial memory, and hippocampus-dependent memory.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as cognitive disorders. The methods relate to a regimen of pulsed dosing of blood plasma or blood plasma fractions.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include reducing the 2-microglobulin (B2M) level in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.